• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

疾病活动度对合并基础风湿性疾病的 SARS-CoV-2 患者临床结局的影响;全球风湿病联盟的数据。

Effect of disease activity on the clinical outcome of SARS CoV-2 in patients with underlying rheumatic diseases; data from global rheumatology alliance.

机构信息

Department of Rheumatology, Foundation University Medical College, Foundation University, Islamabad, Pakistan.

Department of Rheumatology, Rheumatology Foundation University Medical College, Fauji Foundation Hospital, Rawalpindi, Pakistan.

出版信息

J Pak Med Assoc. 2024 Jun;74(6):1055-1060. doi: 10.47391/JPMA.9371.

DOI:10.47391/JPMA.9371
PMID:38948971
Abstract

OBJECTIVES

To determine the effect of disease activity on clinical outcomes of coronavirus disease-2019 in patients with rheumatic diseases.

METHODS

The prospective, cohort study was conducted from January 1st to June 30th, 2021, at Rheumatology department, Fauji Foundation Hospital, Rawalpindi. It comprised patients of rheumatic disorders who were affected by coronavirus disease-2019. The patients were categorised according to rheumatic disease activity into remission group I, low disease activity group II, moderate group III and high-activity group IV. Coronavirus disease-2019 outcomes compared included recovered vs death, hospitalisation yes vs no, mechanical ventilation yes vs no. The association of disease activity status with coronavirus disease-2019 outcomes was explored. Data was analysed using SPSS 23.

RESULTS

Of the 100 patients, 78(78%) were females and 22(22%) were males. The overall mean age was 45.60±13.7 years. There were 23(23%) patients in group I, 42(42%) patients in group II, 21(21%) patients in group III and 14(14%) patients in group IV. Overall,17(17%) patients died and 83(83%) patients survived. In group III, 7(33.3%) patients died, followed by 6(42.9%) in group IV (p<0.05). In total, 7(7%) patients needed mechanical ventilation, with 3(21.4%) being in group IV (p<0.05). Hospitalisation was needed in 33(33%) cases, and intergroup comparison was non-significant (p>0.05).

CONCLUSIONS

Patients with severe rheumatic autoimmune disease affected by coronavirus disease-2019 were more likely to die and require invasive ventilation.

摘要

目的

确定疾病活动度对风湿性疾病患者 2019 年冠状病毒病临床结局的影响。

方法

这项前瞻性队列研究于 2021 年 1 月 1 日至 6 月 30 日在拉瓦尔品第的法乌吉基金会医院风湿病科进行,纳入了受 2019 年冠状病毒病影响的风湿性疾病患者。根据疾病活动度将患者分为缓解组 I、低疾病活动组 II、中组 III 和高活动组 IV。比较了 2019 年冠状病毒病的结局,包括康复与死亡、住院与未住院、机械通气与未通气。探讨了疾病活动状态与 2019 年冠状病毒病结局的关系。数据使用 SPSS 23 进行分析。

结果

在 100 名患者中,78(78%)为女性,22(22%)为男性。总体平均年龄为 45.60±13.7 岁。I 组 23(23%)例,II 组 42(42%)例,III 组 21(21%)例,IV 组 14(14%)例。共有 17(17%)名患者死亡,83(83%)名患者存活。在 III 组中,7(33.3%)名患者死亡,其次是 IV 组的 6(42.9%)(p<0.05)。总共 7(7%)名患者需要机械通气,其中 4(21.4%)例在 IV 组(p<0.05)。需要住院治疗的患者有 33(33%)例,组间比较无显著性差异(p>0.05)。

结论

受 2019 年冠状病毒病影响的严重风湿性自身免疫性疾病患者更有可能死亡并需要侵入性通气。

相似文献

1
Effect of disease activity on the clinical outcome of SARS CoV-2 in patients with underlying rheumatic diseases; data from global rheumatology alliance.疾病活动度对合并基础风湿性疾病的 SARS-CoV-2 患者临床结局的影响;全球风湿病联盟的数据。
J Pak Med Assoc. 2024 Jun;74(6):1055-1060. doi: 10.47391/JPMA.9371.
2
Association of Race and Ethnicity With COVID-19 Outcomes in Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance Physician Registry.种族和民族与风湿性疾病 COVID-19 结局的关联:来自 COVID-19 全球风湿病联盟医师注册处的数据。
Arthritis Rheumatol. 2021 Mar;73(3):374-380. doi: 10.1002/art.41567. Epub 2021 Feb 2.
3
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.风湿性疾病患者因 COVID-19 住院的相关特征:来自 COVID-19 全球风湿病联盟医生报告登记处的数据。
Ann Rheum Dis. 2020 Jul;79(7):859-866. doi: 10.1136/annrheumdis-2020-217871. Epub 2020 May 29.
4
COVID-19 in rheumatic diseases in Italy: first results from the Italian registry of the Italian Society for Rheumatology (CONTROL-19).意大利风湿病学 COVID-19 :意大利风湿病学会(CONTROL-19)意大利登记处的初步结果。
Clin Exp Rheumatol. 2020 Jul-Aug;38(4):748-753. Epub 2020 Jul 28.
5
Clinical Characteristics, Prognostic Factors, and Outcomes of COVID-19 in Autoimmune Rheumatic Disease Patients: A Retrospective Case-Control Study from Astana, Kazakhstan.《哈萨克斯坦阿斯塔纳 COVID-19 自身免疫性风湿病患者的临床特征、预后因素和结局:一项回顾性病例对照研究》
Medicina (Kaunas). 2024 Aug 23;60(9):1377. doi: 10.3390/medicina60091377.
6
Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?COVID-19 疫情期间的风湿性疾病生物制剂:是敌是友?
RMD Open. 2021 Jan;7(1). doi: 10.1136/rmdopen-2020-001439.
7
Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study.COVID-19 住院患者合并慢性炎症和自身免疫性风湿性疾病的临床结局:一项多中心匹配队列研究。
Ann Rheum Dis. 2020 Dec;79(12):1544-1549. doi: 10.1136/annrheumdis-2020-218296. Epub 2020 Aug 12.
8
COVID-19 outcomes among rheumatic disease patients in Kuwait: Data from the COVID-19 Global Rheumatology Alliance (C19-GRA) physician registry.科威特风湿性疾病患者的 COVID-19 结局:来自 COVID-19 全球风湿病联盟(C19-GRA)医生登记处的数据。
Int J Rheum Dis. 2022 Jul;25(7):743-754. doi: 10.1111/1756-185X.14332. Epub 2022 May 11.
9
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry.风湿性疾病患者 COVID-19 相关死亡的相关因素:来自 COVID-19 全球风湿病联盟医生报告登记处的结果。
Ann Rheum Dis. 2021 Jul;80(7):930-942. doi: 10.1136/annrheumdis-2020-219498. Epub 2021 Jan 27.
10
Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases.年龄较大、合并症、糖皮质激素的使用和疾病活动度是炎症性风湿和肌肉骨骼疾病患者 COVID-19 住院的危险因素。
RMD Open. 2021 Jan;7(1). doi: 10.1136/rmdopen-2020-001464.

引用本文的文献

1
[COVID-19 vaccines efficacy and infection features in patients with systemic sclerosis: A single-center cohort study].[新冠病毒疫苗对系统性硬化症患者的疗效及感染特征:一项单中心队列研究]
Beijing Da Xue Xue Bao Yi Xue Ban. 2024 Dec 18;56(6):1041-1046. doi: 10.19723/j.issn.1671-167X.2024.06.015.